Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04768855 | A Study of LY3540378 in Healthy Participants | PHASE1 | COMPLETED | 134 | — | — | Mar 17, 2021 | May 30, 2022 | Jun 21, 2022 | 2 | United States, Singapore |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3540378 (Part A) | EXPERIMENTAL | Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC). |
| LY3540378 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC. |
| LY3540378 (Part C) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Japanese Participants. |
| LY3540378 (Part D) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Chinese Participants. |
| Placebo (Part A, B, C & D) | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3540378 | DRUG | Administered IV or SC. |
| Placebo | DRUG | Administered IV or SC. |
Inclusion Criteria: * Overtly healthy males or females, as determined by medical history and physical examination. * Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²) * For Part C, participants should be first generation Japanese origin. * For Part D, participan...